Should Reporters Have Agreed To The Vertex Embargo?

This morning at 7 a.m., Vertex Pharmaceuticals released big news: adding a new drug, lumacaftor, to its existing cystic fibrosis drug Kalydeco increased by an order of magnitude the number of patients the medicine can help -- although the combo is still not as effective as Kalydeco is in patients who have a particular, rare mutation. I had a story up at 7:05. Adam Feuerstein at TheStreet.com, Andrew Pollack at the New York Times, and Meg Tirrell at CNBC all published their stories at the same time.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news